Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.2: prohibited at all times. Specified. [1]
S4.2 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Clinical safety evidence
A published case describes persistent optic-nerve injury after cyclofenil use as a fertility adjunct. The patient had taken a double dose after a missed dose. The authors considered a possible association; one case cannot establish a causal mechanism or how often this occurs. [2]
- Case report, not a controlled trial or population risk estimate. The paper’s description of cyclofenil as a steroid is not adopted here.
What remains uncertain
- Current authorization and an original prescribing label were not verified. The separate efficacy-study page returned no substantive text.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- Cyclofenil possible ischemic optic neuropathy ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.